Stocktoria
Karyopharm Therapeutics Inc. KPTI
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2013-11-06
Karyopharm Therapeutics Inc. statistics & valuation
Market cap$231.4M
P / S1.6×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -62.1% | -82.2% | -88.7% | -90.5% | -46.8% |
| Net margin | -134.2% | -52.6% | -98.0% | -105.2% | -59.1% |
| FCF margin | -51.6% | -87.9% | -63.5% | -95.3% | -51.2% |
| Return on assets | -180.8% | -46.5% | -59.5% | -46.1% | -40.6% |
| Return on equity | 66.9% | 41.1% | 105.1% | 992.4% | 155.7% |
| Debt / equity | — | — | — | — | -2.12× |
| Current ratio | 1.12 | 1.70 | 3.37 | 5.31 | 3.74 |
| Revenue growth | 0.6% | -0.5% | -7.0% | -25.1% | 94.1% |
Source: SEC EDGAR filings · CIK 0001503802 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.